Hinge Health Inc (HNGE) Stock Analysis

Verdict: WATCH (do not buy)

Digital health leadership drives 84.5% margins, but a 77.5x P/E and heavy insider selling limit near-term upside.

Investment score: 51/100

Analysis as of

Is Hinge Health Inc stock worth reviewing? AI model thesis

Hinge Health shows stellar cash flow and gross margin execution, but trading at 77.5x P/E near all-time highs with significant insider liquidations makes current levels unappealing for new capital entry.

7-factor investment score

Hinge Health Inc opportunities and risks

What speaks for HNGE

What speaks against HNGE

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
HNGE77.5x11.7x78.6x84.5%15.1%3.4%
DGX25.0x2.3x14.4x33.1%9.2%4.6%
GHn/a19.1xn/a65.0%-38.3%-1.1%
LH26.5x1.8x15.2x27.8%7.0%4.4%
BTSG43.7x0.9x22.2x12.4%2.0%3.3%
DVA16.1x0.9x8.0x31.0%6.0%13.5%
Peer median25.0x1.8x14.4x31.0%6.0%4.4%

Frequently asked questions about Hinge Health Inc (HNGE)

Is HNGE stock a good investment?

The cached TradeMates AI model rates Hinge Health Inc as WATCH (do not buy) with an investment score of 51/100. Hinge Health shows stellar cash flow and gross margin execution, but trading at 77.5x P/E near all-time highs with significant insider liquidations makes current levels unappealing for new capital entry. This is algorithmic model output, not personal investment advice.

Is HNGE stock a buy?

The TradeMates model verdict for HNGE is WATCH (do not buy) with an investment score of 51/100. Treat this as a model signal to review, not a personal buy recommendation.